Jump to content
Invision Community
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
META-99 SEARCH ENGINE             CONTACT US

All Activity

This stream auto-updates     

  1. Last week
  2. Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community. Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Drug Conjugates Market (5th Edition), 2019-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: · A detailed assessment of the current market landscape of ADCs. · Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios. · An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs. · A list of key opinion leaders (KOLs) within this domain. · An insightful competitiveness analysis of biological targets. · An analysis of the partnerships that have been established in the recent past. · An analysis of the investments made. · A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April). · An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch. · An analysis of the key promotional strategies that have been adopted by the developers of marketed products. · An assessment of the various therapeutics that are being evaluated in combination with ADCs. · A review of the evolution of ADC conjugation technologies. · An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. · An elaborate discussion on various factors that form the basis for the pricing of ADC products. · A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain. · A case study on companies offering companion diagnostics. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Type of payload · MMAE · DM4 · Camptothecin · AM1 · MMAF Type of linker · VC · Sulfo-SPDB · SMCC · VA · Hydrazone linker · Others Target Indications · Breast Cancer · Lymphoma · Leukemia · Urothelial cancer · Lung cancer · Ovaria cancer · Others Target Antigen · CD30 · HER2 · CD22 · CD33 · Others · Small Molecule Technology Providers · Seattle Genetics · ImmunoGen · StemCentRx · Immunomedics · Others Key Geographies · North America · Europe · Asia Pacific Transcripts of interviews held with the following senior level representatives of stakeholder companies: · Alan Burnett (Professor, School of Medicine, Cardiff University) · Aldo Braca (President and Chief Executive Officer) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals) · Anthony DeBoer (Director, Business Development, Synaffix) · Christian Bailly (Director of CDMO, Pierre Fabre) · Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics) · Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma) · John Burt (Chief Executive Officer, Abzena) · Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions) · Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza) · Mark Wright (Site Head, Piramal Healthcare) · Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia) · Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services) · Toshimitsu Uenaka (Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai) · Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics) Key companies covered in the report · Bristol Myers Squibb · AbbVie · Astellas Pharma · AstraZeneca · Daiichi Sankyo · Pfizer · Roche / Genentech · Synthon · Bayer HealthCare · Biotest Pharmaceuticals For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  3. Earlier
  4. Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes: · A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s). · Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics. · A detailed review of the current market landscape of microbiome diagnostic tests, brief profiles of popular diagnostic developers and indicative list of screening and profiling test kits. · A detailed assessment of the current market landscape of FMT therapies, a geographical clinical trial analysis and information on various stool banks. · A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework. · An analysis of the varied microbiome-focused initiatives of big pharma players. · An analysis of the start-ups / small-sized players engaged in the development of microbiome therapeutics and diagnostics. · An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs. · An analysis of the investments made at various stages of development in start-ups / small-sized companies. · An indicative list of contract manufacturers, in-house manufacturers and CROs that currently claim to have the necessary capabilities. · An assessment of the emerging role of big data highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from in the microbiome research. · An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products · A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) segments: · Type of Therapy (Tx) · Prescription Drug · Prebiotics · Probiotics · Type of Molecule (Tx) · Small Molecules · Biologics · Target Indication (Tx+Dx) · Acne Vulgaris · Atopic Dermatitis · Clostridium difficile Infection · Colorectal Cancer · Crohn’s Disease · Diabetes · Irritable Bowel Syndrome · Lactose Intolerance · Lung Cancer · Nonalcoholic steatohepatitis (NASH) · Obesity · Ulcerative colitis · Therapeutic Area (Tx+Dx) · Autoimmune Disorders · Dental Disorders · Digestive and Gastrointestinal Disorders · Dermatological Disorders · Infectious Disease · Metabolic Disorders · Oncology · Others · Key Geographical Regions (Tx+Dx) · North America · Europe · Asia-Pacific and Rest of the World Key companies covered in the report · 4D Pharma · Armata Pharmaceuticals · Evelo Biosciences · Rebiotix (Acquired by Ferring Pharmaceuticals) · Seres Therapeutics · Vedanta Biosciences For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  5. Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion by 2030, claims Roots Analysis Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. In addition to other elements, the study includes: · A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs. · A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations. · Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion). · An analysis of the partnerships that have been established in this domain, in the recent past. · An analysis of the various expansion initiatives undertaken by the players in this domain. · An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain. · A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO. · A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution. · A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain. · A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) · Type of Product · HPAPIs · Highly Potent Finished Dosage Forms · Company Size · Small-sized · Mid-sized · Large / Very Large · Scale of Operation · Preclinical / Clinical · Commercial · Type of Pharmacological Molecule · Small Molecules · Biologics · Type of Highly Potent Finished Dosage Form · Injectables · Oral Solids · Creams · Others · Key geographical regions · North America · Europe · Asia Pacific · Rest of the World The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies: · Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals) · Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics) · Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research) · Jennifer L Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions) · Roberto Margarita (Business Development Director, CordenPharma) · Allison Vavala (Senior Manager, Business Development, Helsinn) · Mark Wright (Site Head, Piramal Healthcare) · Javier E. Aznárez Araiz (Business Development Technician, Idifarma) Key companies covered in the report · AbbVie Contract Manufacturing · CARBOGEN AMCIS · Catalent · Evonik · Formosa Laboratories · Intas · Lonza · MabPlex · Pfizer CentreOne For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  6. The fragment-based drug discovery market is estimated to be worth around USD 1.6 billion by 2030, predicts Roots Analysis Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: · A detailed review of the overall landscape of fragment-based drug discovery library and service providers. · Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). · An analysis of the partnerships that have been established in the recent past. · A detailed analysis on acquisition targets. · An insightful competitiveness analysis of fragment-based drug discovery library and service providers. · An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach. · A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) · Type of Technique · X-ray Crystallography · Nuclear Magnetic Resonance · Surface Plasmon Resonance · Other Screening Techniques · Type of Service · Library Screening · Fragment Screening · Fragment Optimization · End User · Industry Players · Non-Industry Players · Key Geographical Region · North America (US and Canada) · Europe (UK, France, Germany, Spain, Italy, and rest of Europe) · Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world) Key companies covered in the report: · 2bind · Charles River Laboratories · ChemAxon · ComInnex · Creative Biolabs · Creative Biostructure · CRELUX · Domainex · Evotec · Red Glead Discovery · SARomics Biostructures · Shanghai ChemPartner · Sygnature Discovery · Vernalis Research For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  7. Given the cost saving potential across different processes and operations, the cell and advanced therapies supply chain management market is projected to grow at an annualized rate of ~25% rapid till 2030 Roots Analysis has done a detailed study on Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics Management Systems, Patient Management Systems, Quality Management Systems, Tracking & Tracing Systems, and Other Software), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 510+ page report, which features 185+ figures and 400+ tables, please visit this link Key Market Insights Presently, over 160 innovative, software-enabled systems are being used to efficiently manage and streamline various aspects of the complex supply chain of cell and advanced therapies Company involved in this domain are putting in significant efforts to develop advanced software solutions and also differentiate their offerings, from those of other industry players, in order to maintain a competitive edge North America is the major hub of innovation in this field, serving as the base for companies of all sizes, which are primarily engaged in developing cloud-based solutions for diverse applications The cell and advanced therapies market is characterized by an elaborate value chain, involving a multitude of processes and several stakeholders, each having a discrete set of priorities and requirements Increase in partnership activity reflects the growing interest of stakeholders in this industry; over 50% of reported deals were established to deploy software solutions for enhancing visibility and supply chain performance An analysis of recent activity on Twitter reveals the increasing interest and ongoing efforts of industry stakeholders in providing needle-to-needle traceability and supply chain orchestration solutions Given their cost saving potential across different processes and operations, we expect the cell and advanced therapy supply chain solutions market to grow at an annualized rate of around 25% over the next decade In the mid-long term, the projected opportunity is anticipated to be well distributed across various global regions, different end uses / applications and mode of deployment of various proprietary software solutions For more information, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapies-supply-chain/260.html Table of Contents 3.1. Context and Background 3.2. An Introduction to Cell and Advanced Therapies 3.2.1. Classification of Advanced Therapy Medicinal Products 3.2.2. Current Market Landscape 3.3. Overview of Cell and Advanced Therapies Supply Chain 3.3.1. Donor Eligibility and Selection 3.3.2. Sample Collection 3.3.3. Manufacturing 3.3.4. Logistics 3.3.5. Patient Verification and Treatment 3.3.6. Challenges Associated with the Cell and Advanced Therapies Supply Chain 3.3.6.1. Process Standardization 3.3.6.2. Packaging and Shipping Qualification 3.3.6.3. Validation of Storage Containers 3.3.6.4. Process Qualification 3.3.6.5. Chain of Custody Documentation 3.3.6.6. Demand Forecastin 3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management 3.4.1. Enterprise Manufacturing System 3.4.2. Laboratory Information Management System 3.4.3. Inventory Management System 3.4.4. Quality Management System 3.4.5. Logistics Management System 3.4.6. Patient Management System 3.4.7. Electronic Clinical Outcome Assessments System 3.4.8. Supply Chain Orchestration Platfor 3.5. Growth Drivers and Roadblocks 3.6. Recent Developments and Upcoming Trends 3.6.1. Blockchain Technology 3.6.2. Internet of Things 3.6.3. Augmented Reality 3.6.4. Big Data Analytics 3.6.5. Artificial Intelligence 4. CURRENT MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape 4.2.1. Analysis by Type of Software Solution 4.2.2. Analysis by Key Specification and Benefits Offered 4.2.3. Analysis by Application 4.2.4. Analysis by Mode of Deployment 4.2.5. Analysis by Scale of Management 4.2.6. Analysis by Regulatory Certifications / Accreditations 4.2.7. Analysis by End User 4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape 4.3.1. Analysis by Year of Establishment 4.3.2. Analysis by Location of Headquarters 4.3.3. Analysis by Company Size 4.3.4. Analysis by Support Services Offered 4.3.5. Leading Developers: Analysis by Number of Software Solutions 5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Methodology 5.3. Assumptions and Key Input Parameters 5.4. Competitiveness Analysis: Software Solution Providers 5.4.1. COP Developers 5.4.2. EMS Developers 5.4.3. IMS Developers 5.4.4. LIMS Developers 5.4.5. LMS Developers 5.4.6. PMS Developers 5.4.7. QMS Developers 5.4.8. TTS Developers 6. CELL AND ADVANCED THERAPIES SUPPLY CHAIN MANAGEMENT: COMPANY PROFILES 6.1. Chapter Overview 6.2. Brooks Life Sciences 6.2.1. Company Overview 6.2.2. Supply Chain Management Software Solution Portfolio 6.2.3. Recent Developments and Future Outlook 6.3. Cryoport 6.3.1. Company Overview 6.3.2. Financial Information 6.3.3. Supply Chain Management Software Solution Portfolio 6.3.4. Recent Developments and Future Outlook 6.4. MasterControl 6.4.1. Company Overview 6.4.2. Supply Chain Management Software Solution Portfolio 6.4.3. Recent Developments and Future Outlook 6.5. SAP 6.5.1. Company Overview 6.5.2. Supply Chain Management Software Solution Portfolio 6.5.3. Recent Developments and Future Outlook 6.6. Savsu Technologies 6.6.1. Company Overview 6.6.2. Financial Information 6.6.3. Supply Chain Management Software Solution Portfolio 6.6.4. Recent Development and Future Outlook 6.7. TraceLink 6.7.1. Company Overview 6.7.2. Financial Information 6.7.3. Supply Chain Management Software Solution Portfolio 6.7.4. Recent Developments and Future Outlook 7. SUPPLY CHAIN ORCHESTRATION PLATFORM: EMERGING TRENDS AND KEY Players 7.1. Chapter Overview 7.2. Supply Chain Orchestration Platforms 7.2.1. Key Functions of Supply Chain Orchestration Platforms 7.2.2. Advantages of Supply Chain Orchestration Platforms 7.2.3. Supply Chain Orchestration Platform Implementation Strategies 7.2.3.1. Building the Required Foundation 7.2.3.2. Incorporating an Appropriate Scheduling System 7.2.3.3. Integration with Core Systems / Processe 7.3. Supply Chain Orchestration Platform: Social Media Trends 7.3.1. Scope and Methodology 7.3.2. Historical Trends in Volume of Tweets 7.3.3. Popular Keyword 7.4. Key Industry Players 7.4.1. Be The Match BioTherapies® 7.4.1.1. Company Overview 7.4.1.2. Financial Information 7.4.1.3. MatchSource®: Software Description 7.4.1.4. Recent Developments and Future Outloo 7.4.2. Clarkston Consulting 7.4.2.1. Company Overview 7.4.2.2. Cell Therapy Orchestration Platform: Software Description 7.4.2.3. Recent Developments and Future Outloo 7.4.3. Haemonetics 7.4.3.1. Company Overview 7.4.3.2. Financial Information 7.4.3.3. EdgeCell®: Software Description 7.4.3.4. Recent Developments and Future Outlook 7.4.4. Hypertrust Patient Data Care 7.4.4.1. Company Overview 7.4.4.2. Hypertrust X-Chain: Software Description 7.4.4.3. Recent Developments and Future Outloo 7.4.5. Lykan Bioscience 7.4.5.1. Company Overview 7.4.5.2. Unnamed Software: Software Description 7.4.5.3. Recent Developments and Future Outlook 7.4.6. MAK-SYSTEM 7.4.6.1. Company Overview 7.4.6.2. T.C.S.: Software Description 7.4.6.3. Recent Developments and Future Outlook 7.4.7. sedApta 7.4.7.1. Company Overview 7.4.7.2. O.S.A.: Software Description 7.4.7.3. Recent Developments and Future Outlook 7.4.8. Stafa Cellular Therapy 7.4.8.1. Company Overview 7.4.8.2. Stafa Cellular Therapy Lab: Software Description 7.4.8.3. Recent Developments and Future Outlook 7.4.9. Title 21 Health Solutions 7.4.9.1. Company Overview 7.4.9.2. Cell Therapy Software: Software Description 7.4.9.3. Recent Developments and Future Outlook 7.4.10. TrakCel 7.4.10.1. Company Overview 7.4.10.2. Financial Information 7.4.10.3. Cell Orchestration Platform: Software Description 7.4.10.4. Recent Developments and Future Outlook 7.4.11. Vineti 7.4.11.1. Company Overview 7.4.11.2. Financial Information 7.4.11.3. Personalized Therapy Management Platform: Software Description 7.4.11.4. Recent Developments and Future Outlook 8. FUNDING AND INVESTMENT ANALYSIS 8.1. Chapter Overview 8.2. Types of Funding 8.3. Cell and Advanced Therapies Supply Chain Management: Funding and Investment Analysis 8.3.1. Analysis by Number of Funding Instances 8.3.2. Analysis by Amount Invested 8.3.3. Analysis by Type of Funding 8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions 8.3.5. Most Active Players: Analysis by Number of Funding Instances 8.3.6. Most Active Investors: Analysis by Number of Funding Instances 8.3.7. Geographical Analysis by Amount Invested 8.4. Concluding Remarks 9. PARTNERSHIPS AND COLLABORATIONS 9.1. Chapter Overview 9.2. Partnership Models 9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships 9.3.1. Analysis by Year of Partnership 9.3.2. Analysis by Type of Partnership 9.3.3. Partner’s Focus Area 9.3.3.1. Analysis by Partner’s Focus Area 9.3.3.2. Analysis by Type of Platform and Partner’s Focus Area 9.3.3.3. Analysis by Type of Partnership Model and Partner’s Focus Area 9.3.4. Software Solution Analysis 9.3.4.1. Analysis by Type of Software Solutions 9.3.4.2. Analysis by Type of Platform and Partnership Model 9.3.5. Most Active Players: Analysis by Number of Partnerships 9.3.6. Geographical Analysis 9.3.6.1. Most Active Players 9.3.6.2. Intercontinental and Intracontinental Agreements 10. SUPPLY CHAIN UTILIZATION USE CASES 10.1. Chapter Overview 10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases 10.2.1. Analysis by Year of Utilization 10.2.2. Analysis by Type of Partner 10.2.2.1. Most Active Users: Distribution by Number of Platform Utilization Instances 10.2.2.2. Geographical Distribution of Users 10.2.3. Analysis by Type of Software Solution 10.2.4. Most Active Players: Analysis by Number of Platform Utilization Agreements 10.2.5. Most Active Players: Regional Analysis by Number of Platform Utilization Agreements 10.2.5.1. Regional Distribution by Type of Software Solutions 10.2.5.2. Intercontinental and Intracontinental Agreements 11. STAKEHOLDER NEEDS ANALYSIS 11.1. Chapter Overview 11.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders 11.2.1. Comparison of Stakeholder Needs 12. COST SAVINGS ANALYSIS 12.1. Chapter Overview 12.2. Key Assumptions and Methodology 12.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 12.3.1. Cost Saving Potential in Sample Collection and Processing, 2019-2030 12.3.2. Cost Saving Potential in Manufacturing, 2019-2030 12.3.3. Cost Saving Potential in Logistics, 2019-2030 12.3.4. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 13. MARKET FORECAST 13.1. Chapter Overview 13.2. Key Assumptions and Forecast Methodology 13.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030 13.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application 13.3.1.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection and Processing, 2019-2030 13.3.1.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for, Manufacturing, 2019-2030 13.3.1.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for, Logistics, 2019-2030 13.3.1.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030 13.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User 13.3.2.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030 13.3.2.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs / Commercial Organizations, 2019-2030 13.3.2.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals / Medical Centers, 2019-2030 13.3.2.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030 13.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution 13.3.3.1. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.2. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.3. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.4. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.5. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.6. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.7. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment 13.3.4.1. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030 13.3.4.2. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030 13.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Scale of Operation 13.3.5.1. Cell and Advanced Therapies Supply Chain Management Market for Clinical Therapies, 2019-2030 13.3.5.2. Cell and Advanced Therapies Supply Chain Management Market for Commercial Therapies, 2019-2030 13.3.6. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography 13.3.6.1. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030 13.3.6.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030 13.3.6.3. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030 13.3.6.4. Cell and Advanced Therapies Supply Chain Management Solutions Market in Rest of the World, 2019-2030 13.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment 13.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection and Processing, 2019-2030 13.4.1.1. Cell Orchestration Platforms Market for Sample Collection and Processing, 2019-2030 13.4.1.1.1. Cell Orchestration Platforms Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.1.2. Cell Orchestration Platforms Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.2. Enterprise Manufacturing Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.2.1. Enterprise Manufacturing Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.2.2. Enterprise Manufacturing Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.3. Inventory Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.3.1. Inventory Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.3.2. Inventory Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.4. Laboratory Information Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.4.1. Laboratory Information Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.4.2. Laboratory Information Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.5. Logistics Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.5.1. Logistics Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.5.2. Logistics Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.6. Patient Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.6.1. Patient Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.6.2. Patient Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.7. Quality Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.7.1. Quality Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.7.2. Quality Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030 13.4.2.1. Cell Orchestration Platforms Systems Market for Manufacturing, 2019-2030 13.4.2.1.1. Cell Orchestration Platforms Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.1.2. Cell Orchestration Platforms Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.2. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030 13.4.2.2.1. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.2.2. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.3. Inventory Management Systems Market for Manufacturing, 2019-2030 13.4.2.3.1. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.3.2. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.4. Laboratory Information Management Systems Market for Manufacturing, 2019-2030 13.4.2.4.1. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.4.2. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.5. Logistics Management Systems Market for Manufacturing, 2019-2030 13.4.2.5.1. Logistics Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.5.2. Logistics Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.6. Patient Management Systems Market for Manufacturing, 2019-2030 13.4.2.6.1. Patient Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.6.2. Patient Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.7. Quality Management Systems Market for Manufacturing, 2019-2030 13.4.2.7.1. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.7.2. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030 13.4.3.1. Cell Orchestration Platforms Market for Logistics, 2019-2030 13.4.3.1.1. Cell Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.1.2. Cell Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.2. Enterprise Manufacturing Systems Market for Logistics, 2019-2030 13.4.3.2.1. Enterprise Manufacturing Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.2.2. Enterprise Manufacturing Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.3. Inventory Management Systems Market for Logistics, 2019-2030 13.4.3.3.1. Inventory Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.3.2. Inventory Management Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.4. Laboratory Information Management Systems Market for Logistics, 2019-2030 13.4.3.4.1. Laboratory Information Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.4.2. Laboratory Information Management Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.5. Logistics Management Systems Market for Logistics, 2019-2030 13.4.3.5.1. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.5.2. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.6. Patient Management Systems Market for Logistics, 2019-2030 13.4.3.6.1. Patient Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.6.2. Patient Management Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030 13.4.4.1. Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030 13.4.4.1.1. Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 13.4.4.1.2. Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 13.4.4.2. Inventory Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030 13.4.4.2.1. Inventory Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 13.4.4.2.2. Inventory Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 13.4.4.3. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030 13.4.4.3.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 13.4.4.3.2. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 14. EXECUTIVE INSIGHTS 14.1. Chapter Overview 14.2. Thermo Fisher Scientific 14.2.1. Company Snapshot 14.2.2. Interview Transcript: Bryan Poltilove, Former General Manager, Cell and Gene Therapy 14.3. Cell and Gene Therapy Catapult 14.3.1. Company Snapshot 14.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer 14.4. McKesson 14.4.1. Company Snapshot 14.4.2. Interview Transcript: Divya Iyer, Senior Director, Corporate Strategy and Business Development, and Jill Maddux, Director, Cell and Gene Therapy Product Strategy 14.5. TrakCel 14.5.1. Company Snapshot 14.5.2. Interview Transcript: Martin Lamb, Former Chief Business Officer 15. CONCLUDING REMARKS 15.1. Chapter Overview 15.2. Key Takeaways 16. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS 17. APPENDIX 2: TABULATED DATA 18. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS Contact Details Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  8. 1. Hair Nah After getting tired of people putting their hands in her hair, Momo Pixel decided to create Hair Nah. This video game has you play as a Black woman traveling between three destinations — Osaka, Havana, and Santa Monica Pier. Throughout the game, players have to try preventing white hands from swooping in to touch your character’s hair. This is an issue that Black women talk about a lot, so the game ended up going viral. You can check out a video of Black women playing it below! 2. Sasha Says Brought to you by Atlanta-based duo Adrian McDaniel and Tremayne Toorie, Sasha Says combines “Simon Says” and “Bop-It” to create a gaming experience that’s perfect for kids. “We felt like it was very important for Black youth to be able to see a Black mascot, especially a Black female mascot, in games,” McDaniel told The Washington Informer. “That isn’t something you get to see very often and we also thought it was important to inspire Black youth to maybe get into development.” 3. Matatu Developers Terry Karungi, Daniel Okalany, Jasper Onono, and Guy Acellam all worked together to bring Matatu, a two-player Ugandan card game, to your phone. The app was immensely popular in Uganda. Back in 2013, the Daily Monitor reported that it had been in the top three most played games in Google Play in Uganda. 4. Treachery In Beatdown City If you’re a fan of fighting games and bringing a little bit of comedy into the experience, you’re going to love Treachery In Beatdown City. Developed by independent games and culture studio, Nuchallenger, the game’s plot centers around saving President Blake Orama from the Ninja Dragon Terrorists he’s been kidnapped by. The game isn’t out yet, but its release date is set for sometime before the end of the year. Until then, you can watch a trailer below. 5. B’Bop and Friends Created by Grefonda Hardy and her daughter Noelle Hardy, B’Bop and Friends is an educational video game that helps children with their reading and writing skills. The game features two male and two female characters whom all have their own storylines. Each character has their own room where they can participate in games and activities that enhance players’ reading skills. B’Bop and Friends also has multiplayer games including tennis and basketball. afrotech.com
  9. 6. Swimsanity! Brothers Khalil and Ahmed Abdullah founded independent game studio Decoy Games. Together, they’ve released Swimsanity! — a multiplayer underwater shooter game. The game will be available on Nintendo Switch, PC, PS4, and Xbox One sometime this summer. 7. SweetXHeart What originally started in 2014 as an independent project turned into something much bigger. With Catt Small’s SweetXHeart (pronounced sweetheart), players are challenged to get through the week as Kara, a 19-year-old from the Bronx. Small describes SweetXHeart as a “slice-of-life-game about microaggressions, race, and gender.” 8. BLeBRiTY With Jesse Williams’ BLeBRiTY, players are tested on their knowledge of Black culture in a charade inspired game. The game boasts over 25 genres, including “HBCUs,” “Momma Phrases,” and more. “We decided to stop waiting and start building. By creating the experiences we like, we’ve tapped into our own cultural zeitgeist, which is so often the source material for pop culture at large,” Williams said, according to Vibe. “BLeBRiTY is an uproariously funny, creative event where everyone can play, learn and laugh their a**es off! We don’t wait to be included anymore, we build and include ourselves.” 9. Black Inventors Match Game Created by, Dr. Leshell Hatley, Black Inventors Match Game is the first mobile app designed to teach Black history that specifically targets kids. Kids follow best friends, Myles and Ayesha, to learn who invented the patents for items like doorknobs, traffic lights, and more. Kids also have their memories tested with a matching game. 10. For The Culture Developed by Ark Creative Company — this app aims to celebrate Black culture by putting a modern spin on charades. For The Culture has over 20 categories, including Celebrities, Historical Figures, and more. Watch a trailer for the app below! afrotech.com
  10. African Americans make up a significant demographic of video gamers, the second largest ethnic group to play, after Asian Americans. Yet, there is a paucity of African Americans in the video game industry. Only 2.5% of game developers are of color. This means that not only are African American tech professionals missing out on obtaining some of the coolest jobs ever, but also there has been an issue with the stereotyping and negative portrayals of black characters in games. As Evan Narcisse, writing for gaming site Kotaku, points out, “When I think about black characters and visions of black life in video games that resonated with me–whether it’s Adewale or Aveline from the Assassin’s Creed games–I have to reckon with the idea that there was very likely no black person making decisions about those characters.” While scarce, there are some black people doing some amazing work in the gaming industry. If you dream about a career in making video games, you will want to know about these top 10 black people in the gaming industry. Andrew Augustin Augustin is the founder and creative director of Notion Games L.L.C.. He is also a Black Entrepreneur Modern Man. Before launching his own company, he worked for Edge of Reality as a character designer, and then as a world-builder for Sims 3 Pets for Xbox 360 and Play Station 3. Gordon Bellamy Bellamy started his career as a lead designer for EA’s Madden franchise. He also served as executive director of the International Game Developers Association. He recently co-founded Hangry Studios, a consulting firm focused on quality assurance and automation for PC, mobile, and virtual reality games. Morgan Gray Gray has been in the video game industry for quite some time. He’s worked on a number of best-selling games including Tomb Raider, Star Wars, and The Bureau: XCOM Declassified. Derek Manns: Manns is the founder of Sungura Games. In an interview with Black Enterprise he said his company, “is primarily African American and is steady.” He offered this advice for those seeking a career in video games, “Those looking to join gaming, make sure you’re good at math. Also, look into schools that offer gaming in undergrad.” Dennis Mathews Mathews is a game developer and founder of Revelation Interactive Game Development. He went to school initially for aerospace engineering but then went on to study game design. Mathews is also a developer for Terrific Studios L.L.C. Marcus Montgomery Montgomery was lead game designer at Glu Mobile. He is also the founder of WeAreGameDevs.com–a platform for supporting diversity in the gaming industry. He made news recently by modifying a black Barbie doll into a game developer doll for his wife who is also a game developer. Joseph Saulter Saulter is the founder of Entertainment Arts Research Inc. a leader in the video game industry. He is the chairman of the International Game Developers Association’s Diversity Advisory Board and the author of a series of game design and development textbooks published by McGraw-Hill. Laura Teclemariam Teclemariam works as a senior product manager for gaming and entertainment giant EA. She graduated with a degree in electrical engineering/computer science from the University of California, Irvine. Lisette Titre ACG artist and computer animator Lisette Titre has contributed to some of EA’s highest profile games, including Tiger Woods Golf for Nintendo’s Wii, The Simpsons, and Dante’s Inferno. Karisma Williams Williams is creative director of Matimeo.com and works at Microsoft as a senior experience developer/designer for Xbox Kinect, which lets players interact with video games without the use of a controller. blackenterprise.com
  11. This is a list of black video game characters. The 2009 study "The virtual census: representations of gender, race and age in video games" published by the University of Southern California showed that African Americans appear in video games in proportion to their numbers in the 2000 US census data, but mainly in sports games and in titles that reinforce stereotypes. Characters 50 Cent of 50 Cent: Bulletproof and 50 Cent: Blood on the Sand Adam Hunter of Streets of Rage Afro Samurai of Afro Samurai Aisha of Rumble Roses and Rumble Roses XX Alyx Vance of Half-Life 2 (mixed Black-Asian descent) Anthony Higgs of Metroid: Other M Augustus Cole of Gears of War Aurelia Hammerlock of Borderlands: The Pre-Sequel Aveline de Grandpré of Assassin's Creed Axel Foley of Beverly Hills Cop Ayme of Baten Kaitos: Eternal Wings and the Lost Ocean Balrog of Street Fighter Bangalore of Apex Legends Baptiste of Overwatch Barret Wallace of Final Fantasy VII Basilio[6] of Fire Emblem Awakening Beatrix LeBeau of Slime Rancher Big Smoke of Grand Theft Auto: San Andreas Birdie of Street Fighter (black only in the Alpha and V series) Black Baron of MadWorld Blacker Baron of Anarchy Reigns Black Panther, appeared in various games; see Black Panther (comics)#Video games Blade, appeared in various games; see Blade (comics)#Video games Bo Jackson, appeared in various games; see Bo Jackson#Video games Boman Delgado of Rival Schools: United by Fate Brad Garrison of Dead Rising Bruce Irvin of Tekken Bryan Roses of Killer Is Dead Carl "CJ" Johnson of Grand Theft Auto: San Andreas Charles Milton Porter of BioShock 2: Minerva's Den Charles Smith of Red Dead Redemption 2 Clementine of The Walking Dead Coach of Left 4 Dead 2 Cyborg, appeared in various games; see Cyborg (comics)#Video games Cyrax of Mortal Kombat Crying Wolf of Metal Gear Solid 4: Guns of the Patriots Daisy Fitzroy of BioShock Infinite Daley Thompson, three Ocean Software games; see Daley Thompson#After athletics Dandara of Dandara D'arci Stern of Urban Chaos Darrius of Mortal Kombat David Anderson of Mass Effect Dee Jay of Street Fighter Demoman of Team Fortress 2 Disco Kid of Punch-Out!! Doc Louis of Punch-Out!! Donald Anderson (DARPA Chief) of Metal Gear Solid Doomfist of Overwatch Drebin 893 of Metal Gear Solid 4: Guns of the Patriots Dudley of Street Fighter Eddie Hunter (aka Skate, aka Sammy Hunter) of Streets of Rage 2 Eddy Gordo of Tekken Elena of Street Fighter Eli Vance of Half-Life Emmett Graves of Starhawk Fortune of Metal Gear Solid 2: Sons of Liberty Fran of Final Fantasy XII Franklin Clinton of Grand Theft Auto V Garcian Smith of Killer7 Grace of Fighting Vipers Heavy D! of The King of Fighters Henry and Sam of The Last of Us Iris of Pokémon Black and White Irving Lambert of Tom Clancy's Splinter Cell Isaac Washington of The House of the Dead: Overkill J.D. Morrison of Devil May Cry 5 Jacob Taylor of Mass Effect Jacqui Briggs of Mortal Kombat Jade of Mortal Kombat James Heller of Prototype Jax of Mortal Kombat Jeffry McWild in Virtua Fighter Jim Chapman of Resident Evil Outbreak Josh Stone of Resident Evil 5 John Dalton of Unreal II: The Awakening Julius Erving (aka Dr. J) of One on One: Dr. J vs. Larry Bird Kai of Mortal Kombat Kendl Johnson of Grand Theft Auto: San Andreas Kenneth J. Sullivan of Resident Evil Kid Quick of Punch-Out!! Knox of Call of Duty: Advanced Warfare LaShawn and Kahlil of Bébé's Kids Laurence Barnes (aka Prophet) of Crysis Lee Everett of The Walking Dead Lenny Summers of Red Dead Redemption 2 Leroy Smith of Tekken Liam Kosta of Mass Effect: Andromeda Lifeline of Apex Legends Lincoln Clay of Mafia III Lisa Hamilton of Dead or Alive Lieutenant Alphanso Adams of Spec Ops: The Line Louis of Left 4 Dead and Left 4 Dead 2 Lucian of League of Legends Lúcio of Overwatch and Heroes of the Storm Lucius Fox, appeared in various video games; see Lucius Fox#Video games Lucky Glauber of The King of Fighters Luke Cage (aka Power Man), appeared in various games; see Luke Cage#Video games Mace Windu of Star Wars Episode I: Jedi Power Battles and Lego Star Wars Mad Jack of Heavy Rain Madd Dogg of Grand Theft Auto: San Andreas Marcus Holloway of Watch Dogs 2 Marcus Howard of Call of Duty WW2 Marina of Splatoon 2 Mark Kimberley of Shenmue Mark Wilkins of Resident Evil Outbreak Marlow Briggs of Marlow Briggs and the Mask of Death Marvin Branagh of Resident Evil Master Raven of Tekken Master Sergeant Matthew "Coops" Cooper of ARMA 2 Matt of Until Dawn Matt of Wii Sports Michael Jackson, appeared in various games; see Michael Jackson-related games (Michael Jackson's health and appearance) Michael Jordan in Michael Jordan in Flight and Michael Jordan: Chaos in the Windy City Michael LeRoi of Shadow Man (video game) Mike Tyson, appeared in various games; see Mike Tyson in popular culture#In video games Mr. Sandman of Punch-Out!! Maya of Killer Instinct Mohammed Avdol of JoJo's Bizarre Adventure Nadine Ross of Uncharted 4: A Thief's End Nathan Copeland of No More Heroes 2: Desperate Struggle Nick Fury, appeared in various games; see Nick Fury in other media#Video games (Not always black.) Nilin of Remember Me Nix of Infamous 2 OG Loc of Grand Theft Auto: San Andreas Qhira of Heroes of the Storm Raven of Tekken Riley Abel of The Last of Us Rochelle of Left 4 Dead 2 Rodin of Bayonetta Roland of Borderlands Romeo of Halo 3: ODST Sam B of Dead Island Samuel Williams of Desperados: Wanted Dead or Alive Sazh Katzroy of Final Fantasy XIII SCAT member Collins of Night Trap Sean Johnson of Grand Theft Auto: San Andreas Sean Matsuda of Street Fighter III Sergeant Cormack of Call of Duty: Advanced Warfare Sergeant Foley of Call of Duty: Modern Warfare 2 Sergeant Major Avery Junior Johnson of Halo Shadow Man of Shadow Man Shaquille O'Neal (aka Shaq), appeared in various games; see Shaquille O'Neal#Video games Sheva Alomar of Resident Evil Shinobu Jacobs of the No More Heroes series Sir Hammerlock of Borderlands 2 Staff Sgt. Griggs of Call of Duty Storm, appeared in various games; see Storm in other media#Video games Tanya of Mortal Kombat Taurus of Interstate '82 Three Dog of Fallout 3 Tiger Jackson of Tekken T.J. Combo of Killer Instinct Tilly Jackson of Red Dead Redemption 2 Tom Johnson of Shenmue Torque of The Suffering Twintelle of Arms Tyler Miles of Fahrenheit Tyrael of Diablo III Vanessa Lewis of Virtua Fighter Victor Vance and his brother Lance Vance, of Grand Theft Auto: Vice City Stories and Grand Theft Auto: Vice City Vivienne, of Dragon Age: Inquisition War Machine, appeared in various games; see War Machine in other media#Video games Wonder-Black of The Wonderful 101 Yelena Fedorva of Deus Ex: Human Revolution Zach Hammond of Dead Space Zack of Dead or Alive Zasalamel of Soulcalibur wikipedia.org
  12. Video games have also had an effect on the ability of racial minorities to express their identities online in semi-protected environments. The limited constraints in regards to character design in multiplayer games, such as Minecraft, allow video game players to alter their outer appearance in game to match their real life appearance as closely as they choose. wikipedia.org
  13. There have been a number of controversies surrounding race and video games, including public debates about Resident Evil 5, Sid Meier's Civilization IV: Colonization, Left 4 Dead 2, BioShock Infinite, World of Warcraft, and Grand Theft Auto: Vice City. Video games may influence the learning of young players about race and urban culture. The portrayal of race in some video games such as the Grand Theft Auto series, Custer's Revenge, 50 Cent: Bulletproof, and Def Jam: Fight for NY has been controversial. The 2002 game, Grand Theft Auto: Vice City was criticized as promoting racist hate crimes. The game takes place in 1986, in "Vice City", a fictionalized Miami. It involves a gang war between Haitian and Cuban refugees which involves the player's character. However, it is possible to play the game without excessive killing. The 2009 game Resident Evil 5 is set in Africa, and as such has the player kill numerous African antagonists. In response to criticism, promoters of Resident Evil 5 argued that to censor the portrayal of black antagonists was discrimination in itself. In 2008, the release of Sid Meier's Civilization IV: Colonization was controversial for giving players the ability to colonize the Americas. For some critics, like Ben Fritz, the game was 'offensive' since it allowed players to do “horrific things .. or whitewash some of the worst events of human history.” Fritz wrote, “the idea that 2K and Firaxis and Sid Meier himself would make and release a game in the year 2008 that is not only about colonization, but celebrates it by having the player control the people doing the colonizing is truly mind boggling.” Firaxis Games' president Steve Martin responded by pointing out how “the game does not endorse any particular position or strategy—players can and should make their own moral judgments.” There was significant backlash against Ben Fritz on online forums and blogs, with gameplayers talking about how colonization has always happened, and this is just realism. Others talked about how colonization and racism are two different things. Rebecca Mir and Trevor Owens write about how 'The game is undoubtedly offensive, but it would be impossible to create a value-free simulation of the colonial encounter. ... if there is something regrettable about the game in its current state, it is that it is not offensive enough. While the game lets you do some rather evil things, those evil things are nevertheless sanitized versions of the events that actually took place in reality.' Ken White says 'Empire-building games always involve conflict — often violent — with other people, and the more sophisticated ones almost always depict stronger groups overcoming weaker groups. Many involve religious or cultural conversion of some sort. Many permit digital genocide, with your little nation of abstractions defeating another little nation of abstractions mercilessly. ... While the graphics, gameplay detail, and level of abstraction vary widely, they all come down to build, manage, conquer, and destroy.' Media theorist Alexander Galloway, in his book, Gaming: Essays on Algorithmic Culture argues about how these kinds of games are always an “ideological interpretation of history” or the “transcoding of history into specific mathematical models.” wikipedia.org
  14. Through interactive gameplay, players learn about race through the types of characters that are portrayed in the virtual reality. The way racial groups are portrayed in video games affects the way video game players perceive defining characteristics of a racial group. The presence or absence of racial groups affects how players belonging to those racial groups see themselves in terms of the development of their own identity and self-esteem. The idea of portraying different races is not something entirely new in the history of video games. Early games, including some MMORPGs like World of Warcraft, featured multiple playable (fictional) races that the player could choose from at the beginning of the game. Compared to the research on gender stereotyping, fewer studies have examined racial stereotyping in video games. Light skin tones are seen as the default skin color for many games. The portrayal of racial minorities in video games has been demonstrated to have a tendency to follow certain racial stereotypes. A study by the Children Now organization in 2001 noted that of the 1,716 video game characters analyzed, all Latino characters "appeared in a sports-oriented game, usually baseball." 83% of African-American males were portrayed as competitors in sports-oriented games, while 86% of African-American females were either "props, bystanders, or participants in games, but never competitors." Research by Anna Everett and Craig Watkins in 2007 claims that since then, the number of black and Latino characters has increased with the rising popularity of "urban/street games," while their portrayal has remained consistently narrow. In the action/shooter genre of urban/street games, both blacks and Latinos are typically portrayed as "brutally violent, casually criminal, and sexually promiscuous." The protagonist of the Just Cause series, Rico Rodriguez, is Hispanic, as is 'Ding' Chavez, protagonist of Tom Clancy's Rainbow Six. In the sports genre, blacks are typically portrayed as "verbally aggressive and extraordinarily muscular and athletic." African Americans are represented as aggressive or athletic characters more often than as protagonists or heroes. In a 2009 survey of 150 games across nine platforms, University of Southern California Professor Dmitri Williams "found that fewer than 3 percent of video game characters were recognizably Hispanic and none were playable. Native Americans and biracial characters were non-existent. Though, Native Americans have been the protagonists of several video games, most notably in the Turok series, and in the 2006 title Prey. African Americans enjoyed a rate of 10.74 percent, with a big caveat; they were mostly athletes and gangsters." In a study that examined the top 10 most-highly rated games for each year from 2007–2012, Ithaca College graduate Ross Orlando found that "black and Asian characters each have 3 percent representation in the pool of main protagonists; Latino a mere 1 percent." In 2015, Pew Research Center found that 35% of blacks, 36% of Hispanics, and 24% of whites surveyed believe that minorities are portrayed poorly in video games. The range of playable characters in certain gaming contexts has an overtly racial component. Some have argued that the high proportion of black male characters in sports video games (according to David J. Leonard, 80% of black male video game characters as of 2003 were sports competitors) have enabled (predominantly white male) gamers to practice what Adam Clayton Powell III refers to as "high-tech blackface", a digital form of minstrelsy that allows white players to effectively 'try on' blackness without being forced to acknowledge or confront the degrading racist histories surrounding minstrelsy. The potential for video games as a site for promulgating reductive, racist tropes has prompted many to point out the use of yellowface, or "the donning and using of the "yellow" body by whites" to degrade and invisiblize Asian characters in a variety of games as well. Anthony Sze-Fai Shiu argues that the Duke Nukem 3D series (including Duke Nukem 3D and its spiritual sequel Shadow Warrior) enable the gamer to identify strongly with the protagonist, due to the first-person perspective employed by the games. "These characters, then, establish a scenario where the player's control over virtual embodiment demands critical decisions concerning subjective investments in the games’ scenarios and narratives. As such, both Duke Nukem 3D’s and Shadow Warrior's speculations concerning white subjectivity and yellowface performance call for an investigation into the value of performing as a racial other for the sake of game play." wikipedia.org
  15. A 2014-2015 report published in 2016 by the International Game Developers Association found that people of color were both underrepresented in senior management roles as well as underpaid in comparison to white developers. Gaming convention organizer Avinelle Wing told Newsweek, "The industry has an even bigger problem with race than it does with gender.” Many have pointed out that this lack of diversity within the industry has contributed to a lack of representation within video games themselves. Dennis Mathews, a game designer at Revelation Interaction Studios, suggests that the exclusion of non-white game developers leads to stereotyping within video game development and marketing. Developer prejudices impact who counts as a game's target audience, leading many developers to pigeonhole or ignore non-white gamers. As Mathews puts it, "Those stereotypes tie into publisher decisions of what games get picked up and what should be put into games." The Game Developers Conference, a popular annual video game conference frequented by both industry and players, runs an "Advocacy Track" to "address new and existing issues within the realm of social advocacy. Topics covered range from diversity to censorship to quality of life." While initially started in 2013 to address issues around gender and gaming, the "Advocacy Track" features panels explicitly interested in improving diversity in gaming more broadly, including concerns around race. One of the earliest pioneers in the gaming industry was African-American engineer Jerry Lawson, who helped develop the first cartridge-based home video game console. Other people of African descent in gaming include industry executive Gordon Bellamy. Notable Hispanics in the gaming industry include John Romero, co-creator of Doom, often called the first true "first-person shooter." wikipedia.org
  1. Load more activity
×
×
  • Create New...